MCD vs REGN · P/E 23, rev $25.92B vs P/E 14, rev $14.34B
McDonald’s Corporation (MCD) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
McDonald’s Corporation (MCD) is a restaurants company listed on NYSE. It is led by Chris Kempczinski.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported MCD revenue for 2024-12-31 was $25.92B. Net income was $8.22B. Revenue was up 1.7% from 2023-12-31 to 2024-12-31. MCD currently screens at market cap $201.66B and trailing P/E 23.4.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MCD currently screens at market cap $201.66B and trailing P/E 23.4. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MCD and REGN stock pages for the full models.
Not investment advice.